AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05279235
Drug: Favipiravir
RxNorm normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Day 1: 1600mg, Q12H X 1 day; Day 2\~5: 600mg, Q12H X 4 days
Trial: NCT05279235
Drug: Favipiravir placebo
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Day 1: 1600mg, Q12H X 1 day; Day 2\~5: 600mg, Q12H X 4 days
Trial: NCT06215989
Drug: Colchicine Pill
RxNorm normalized name: colchicine Pill
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine 0.5mg once daily will be given on the basis of standard treatment of ACS recommended by guidelines
Trial: NCT05475990
Drug: Hydroxyethyl starch
RxNorm normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Trial: NCT05475990
Drug: Crystalloid
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Trial: NCT04860518
Drug: IFN beta-1a
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treated daily with IFN beta-1a 10 μg as an IV bolus for 6 days while hospitalised
Trial: NCT04860518
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treated daily with dexamethasone 6 mg as an IV bolus for 6 days while hospitalised
Trial: NCT06272032
Drug: intranasal corticosteroids, oral antihistamines, oral leukotriene receptor antagonists, and intranasal antihistamines
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intranasal corticosteroids, oral antihistamines, oral leukotriene receptor antagonists, and intranasal antihistamines and other therapies.
Trial: NCT05866354
Drug: Tisotumab Vedotin
RxNorm normalized name: Tisotumab vedotin
DrugBank: Tisotumab vedotin (DB16732)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tisotumab vedotin is an antibody-drug conjugate (ADC) targeting tissue factor (TF), a protein aberrantly expressed in a wide number of solid tumors including cervical cancer.
Trial: NCT04977336
Drug: VX-548
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration.
Trial: NCT00002294
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05171751
Drug: Octreotide Injection
RxNorm normalized name: octreotide Injection
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide subcutaneous injection for congenital hyperinsulinemia with ineffective diazine
Trial: NCT06451900
Drug: Fenofibrate
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: full-term (37 to 41 weeks), Appropriate for gestational age weight between 2500 to 3500 gm infants and with neonatal hyperbilirubinemia not reaching the level of phototherapy were randomised to receive the drug in different doses or in the control group
Trial: NCT05158296
Drug: Ultevursen
RxNorm normalized name: Ultevursen
DrugBank: Ultevursen (DB17835)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RNA antisense oligonucleotide for intravitreal injection
Trial: NCT04876079
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A subcutaneous insulin bolus will be given to induce a decline in plasma glucose and reach the glycemic threshold.
Trial: NCT06447597
Drug: B007
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: B007 high dose and low dose： Subcutaneous injection was administered on days 1 and 15
Trial: NCT05001724
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib is RP3D milligram per day, every day.
Trial: NCT05001724
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel is 75 milligram per Square meter, every 3 weeks.
Trial: NCT04525014
Drug: RRx-001
RxNorm normalized name: RRx-001
DrugBank: RRx-001 (DB12060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRx-001 will be administered every 3 weeks via intravenous infusion at three dose levels: 0.5 mg/m2 (Max 1 mg), 1 mg/m2 (Max 2 mg), and 2 mg/m2 (Max 4 mg).
Trial: NCT04525014
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg/m2 (children ≥0.5 m2) or 3 mg/kg (children \<0.5 m2) daily for 5 days beginning on day 1 of each cycle
Trial: NCT04525014
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 90 mg/m2 taken orally daily for 5 days administered 1 hour after temozolomide
Trial: NCT05277636
Drug: 3,4-methylenedioxymethamphetamine
RxNorm normalized name: 3,4-Methylenedioxymethamphetamine
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of 125 mg racemic MDMA will be administered.
Trial: NCT05277636
Drug: S-3,4-methylenedioxymethamphetamine
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of 125 mg enantiomeric S-MDMA will be administered.
Trial: NCT05277636
Drug: R-3,4-methylenedioxymethamphetamine (125 mg)
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of 125 mg enantiomeric R-MDMA will be administered.
Trial: NCT05277636
Drug: R-3,4-methylenedioxymethamphetamine (250 mg)
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of 250 mg enantiomeric R-MDMA will be administered.
Trial: NCT05193916
Drug: chiglitazar sodium tablets
RxNorm normalized name: sodium fluoride Oral Tablet
DrugBank: Chiglitazar (DB19023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the drugs will be given orally once a day
Trial: NCT04448834
Drug: Blinatumomab
RxNorm normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: liposomal vincristine 2.25 mg/m2 weekly x 3 per cycle (weeks 3-5 in cycle 1 and 2-4 in subsequent cycles)
Trial: NCT04774419
Drug: Dostarlimab
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV Dostarlimab every 3 weeks for 4 cycles followed by 1 dose of 1000mg (C5). Patients will receive a maximum of 5 cycles of Dostarlimab.
Trial: NCT04715542
Drug: Stibium metallicum praeparatum 6x
RxNorm normalized name: Aluminium metallicum
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stibium metallicum praeparatum 6x will be administered with subcutaneous injections 3 times a week at 1 ampoule at 1 mL during the chemotherapy and shall be continued during 6 weeks after the end of chemotherapy . The first injection will be administered on the day of the first dose of chemotherapy, before the injection of the first dose of chemotherapy.
Trial: NCT06524063
Drug: Survivin-loaded dendritic cell injection
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The injections will be given on days 0, 14, and 28. The administration will involve both intradermal (ID) and intravenous (IV) routes.
Trial: NCT05529875
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous propofol using target-controlled infusion (TCI) devices.
Trial: NCT05529875
Drug: sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: inhalator sevoflurane using sevoflurane vaporizer sevoflurane vaporizer.
Trial: NCT06667934
Drug: Methalazine suppository was given rectally once a day
RxNorm normalized name: METHDILAZINE
DrugBank: Methdilazine (DB00902)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methalazine suppository was given rectally once a day
Trial: NCT06664970
Drug: Azacitidine or Ruxolitinib combined with Selinexor
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1. The initial dose of Selinexor combined with Azacitidine for the treatment of MDS patients is 40mg QW, adjusted according to blood tests, with the highest dose ≤ 60mg QW.~   Azacitidine: The initial dose is 75 mg/m ², administered subcutaneously or intravenously, with a cycle of 1-7 days and 28 days until ineffective or intolerant.~2. Selinexor combined with Ruxolitinib for the treatment of patients with MPN symptoms: Selinexor dose: 40mg QW; Adjust according to the blood count, with a maximum dose of ≤ 60mg QW.~Initial dose of Ruxolitinib: platelet count\>100 × 109/L before enrollment, initial dose is 15 mg BID; Platelets range from 50-100 × 109/L, with an initial dose of 10 mg BID. Until ineffective or intolerant.
Trial: NCT05701956
Drug: Tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds) before endovascular thrombectomy
Trial: NCT06682182
Drug: Tislelizumab+SOX
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OX: S-1 dosing based on body surface area (BSA): \<1.25m², 40 mg bid orally, 1.25-\<1.5m², 50 mg bid orally, ≥1.5m², 60mg bid orally, days 1-14; Q3W; Oxaliplatin 130mg/m² IV day 1, for a total of 6 cycles.~Tislelizumab: 200mg IV, day 1, Q3W, for a total of 6 cycles. HIPEC: Docetaxel 75mg/m² in 3500ml normal saline, at 43°C for 60 minutes.
Trial: NCT06482294
Drug: Salbutamol
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One arm is a combination of salbutamol and fluticason as a rescue medication (anti-inflammatory rescue medication). The second arm is salbutamol only as a rescue medication (non-anti-inflammatory rescue medication).
Trial: NCT06482294
Drug: Fluticason either Beclometasone or Budesonide
RxNorm normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One arm is a combination of salbutamol and an ICS as a rescue medication (anti-inflammatory rescue medication). The second arm is salbutamol only as a rescue medication (non-anti-inflammatory rescue medication).
Trial: NCT05204927
Drug: Abiraterone with Prednisone or Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hormone Therapy
Trial: NCT06665087
Drug: PD-1 antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab
Trial: NCT06665087
Drug: Chemotherapy (Fluorouracil)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-Fluorouracil or capecitabine
Trial: NCT06665087
Drug: Chemotherapy (Raltitrexed)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltitrexed
Trial: NCT06665087
Drug: Chemotherapy (Oxaliplatin)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin
Trial: NCT06665087
Drug: Chemotherapy (CPT-11)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan
Trial: NCT06058520
Drug: Fecal Microbiota - lyophilized
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive 2 capsules daily for one week followed by one capsule daily for 2 weeks. MTT capsules are derived from a single donor per patient.
Trial: NCT06061523
Drug: Sotorasib
RxNorm normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Tablet
Trial: NCT05331755
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: start medication in cohort
Trial: NCT06209970
Drug: HA35
RxNorm normalized name: Hyaluronic Acid 35
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All the freshly made HA35 or B-HA samples were diluted to a final concentration of 5 mg/ml. The filter membrane with 220nm pore size was used to filter freshly made HA35 or B-HA injection in order to test its human tissue permeability as \<220nm nino-particle.
Trial: NCT05352854
Drug: 0.5% pilocarpine eye drops
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be given 0.5% pilocarpine eye drops every five minutes for three times and wait for 40 minutes
Trial: NCT03843463
Drug: Escitalopram 10mg
RxNorm normalized name: Escitalopram 10mg Oral tablet
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram tablet
Trial: NCT05283980
Drug: 0.25% Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention group/ bupivacaine group will receive up to 25 ml of 0.25% bupivacaine hydrochloride for the Pecs block in comparison to the control group that would receive 0.9% normal saline
Trial: NCT05172440
Drug: tislelizumab combined with axitinib
RxNorm normalized name: Tislelizumab
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects received axitinib 5 mg bid, 12 weeks, and tislelizumab 200 mg on the first day of the first week, 4th week, 7th week, and 10th week, and intravenous infusion. With 21 days as a treatment cycle, 4 cycles of treatment, namely 12 weeks. Axitinib was discontinued for 12 weeks after the completion of treatment, and surgery was performed 7 days later.
Trial: NCT06682351
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 16 weeks of using metformin: Dosing will initiate at 500mg TID and increased to 1000mg BID after one week.
Trial: NCT06682351
Drug: GLP-1A
RxNorm normalized name: (Gly2)GLP-2
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 16 weeks using GLP1a: Dosing will be titrated per clinical guidelines and as per FDA approved clinical protocols.
Trial: NCT04734990
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV or SC
Trial: NCT04734990
Drug: Seclidemstat
RxNorm normalized name: Seclidemstat
DrugBank: Seclidemstat (DB17117)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05751512
Drug: MRG003
DrugBank: MRG-003 (DB17407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT05751512
Drug: Cetuximab injection
RxNorm normalized name: cetuximab Injection
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously
Trial: NCT04879121
Drug: Larotrectinib Sulfate
RxNorm normalized name: Larotrectinib sulfate
DrugBank: Larotrectinib (DB14723)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05265442
Drug: Methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: titration of Zoryon (methadone): increase of posology untill pain relieved is reached
Trial: NCT06682611
Drug: SG001
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In accordance with the protocol
Trial: NCT06682611
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In accordance with the protocol
Trial: NCT06682611
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In accordance with the protocol
Trial: NCT06682611
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In accordance with the protocol
Trial: NCT05035914
Drug: Anlotinib Hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.
Trial: NCT06682611
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In accordance with the protocol
Trial: NCT06682611
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In accordance with the protocol
Trial: NCT06682611
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: In accordance with the protocol
Trial: NCT03850730
Drug: Pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Active pharmaceutical ingredient plus excipients filled into a capsule for the lower dosing necessary in this study
Trial: NCT06304350
Drug: Combination of pembrolizumab and platinum containing dual drugs
RxNorm normalized name: combinations of levothyroxine and liothyronine
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After 2 courses of treatment with a combination of pembrolizumab and platinum containing dual drugs (albumin paclitaxel+carboplatin), surgery was performed and pembrolizumab immunomaintenance therapy continued after surgery
Trial: NCT05360160
Drug: SNDX-5613
RxNorm normalized name: anti-Csf1R monoclonal antibody SNDX-6352
DrugBank: Axatilimab (DB16388)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT05360160
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by PO
Trial: NCT06667050
Drug: Chemotherapy plus sintilimab and bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Laparoscopic exploration should be performed to detect occult peritoneal metastases and inspect the primary lesion, liver, diaphragm, pelvic organs, bowel and omentum.~3 cycles of neoadjuvant therapy will be administered: capecitabine: 100 mg/m2, Bid, d1-14, q3w; oxaliplatin: 130 mg/m2, iv drip, d1, q3w; sintilimab: 200 mg, iv drip, d1, bevacizumab biosimilar (IBI305) 10mg~/Kg, iv drip, d1, q3w. Radical D2 gastric cancer resection will be performed within 6-8 weeks after the last administration of chemotherapy plus sintilimab and bevacizumab biosimilar (IBI305).~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with CAPOX regimen for up to 3 cycles.
Trial: NCT05672979
Drug: Brolucizumab Injection [Beovu]
RxNorm normalized name: brolucizumab Injection [Beovu]
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: brolucizumab 6mg intravitreal injection
Trial: NCT05429970
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol 20 mg PO BID (for 21 consecutive days), Propranolol 10mg PO BID (for 3 consecutive days POD 14-16)
Trial: NCT04073433
Drug: Midomafetamine HCl
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg midomafetamine HCl
Trial: NCT06457425
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For patients with platelet counts between 100×10\^9/L and 200×10\^9/L, the recommended starting dose is 15 mg twice daily (bid). For patients with platelet counts \>200×10\^9/L, the recommended starting dose is 20 mg bid. For patients with platelet counts between 50×10\^9/L and \<100×10\^9/L, the recommended maximum starting dose is 5 mg bid.
Trial: NCT04544293
Drug: Molgramostim
RxNorm normalized name: molgramostim
DrugBank: Molgramostim (DB12525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molgramostim 300 µg nebulizer solution
Trial: NCT05426486
Drug: Pyrotinib maleate
RxNorm normalized name: maleate
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGFR/HER2 dual inhibitor
Trial: NCT05426486
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-Her2 monoclonal antibody
Trial: NCT05426486
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-HER2 monoclonal antibody
Trial: NCT05426486
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cytotoxic chemotherapy
Trial: NCT05426486
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytotoxic chemotherapy
Trial: NCT06598462
Drug: Solrikitug Low Dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Solrikitug (DB19301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solrikitug low dose subcutaneous injection
Trial: NCT06598462
Drug: Solrikitug Mid Dose
RxNorm normalized name: Solrikitug
DrugBank: Solrikitug (DB19301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solrikitug mid dose subcutaneous injection